| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2f8286bda7003011f8b1f980a515c8ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b20ad909fe719dc290d0adb9ab77089 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate |
2012-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_260061f6118fab4907f493ca5dfd1a86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71f225ef2f35b1d0039e65bd9095d29e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afe3f560a20dfb39b5d5a0f88a8241d7 |
| publicationDate |
2013-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2013157965-A1 |
| titleOfInvention |
Prevention and Treatment of Oxidative Stress Disorders by Glutathione and Phase II Detoxification Enzymes |
| abstract |
The present invention generally relates to the field of treating oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in animal tissue. The present invention also relates to the field of protecting a subject from oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in the subject. The present invention also relates to a pharmaceutical composition useful for the treatment of oxidative stress disorders. |
| priorityDate |
2001-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |